FibroBiologics, Inc. Common Stock
FBLGNASDAQHealthcareBiotechnology
Previous close
$1.44
+$0.15 · +11.63%
FBLG company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
23
Expensive
Momentum
20
Strong Down
Sentiment
46
Mixed
Risk resilience
27
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteFibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Peter O'Heeron
- Listed since
- Feb 1, 2024
- Employees
- 15
Market position
Day range
Current $1.44
52-week range
Current $1.44
- Open
- $1.355
- Previous close
- $1.29
- Volume
- 570.61K
- 2.56× average
- Average volume
- 223.19K
- Average daily volume
- Market cap
- 3.02M USD
- Beta
- 1.22
- Market reference 1
- 50-day average
- $0.8818
- +63.30% above average
- 200-day average
- $3.5223
- -59.12% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 7.56M USD
- P/E (TTM)
- -0.26×
- P/B (TTM)
- 1.95×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.43×
- Earnings yield
- -185.56%
- Free cash flow yield
- -165.75%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -302.89%
- Return on assets
- -193.85%
- Return on invested capital
- -194.36%
Financial health
- Debt / equity
- 0.32×
- Current ratio
- 3.61×
- Altman Z-score
- -17.5
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 832K USD | — | — | — | — |
| Gross profit | −832K USD | — | — | — | — |
| Research and development | 7.41M USD | 4.5M USD | 2.37M USD | 1.15M USD | 521K USD |
| Selling, general, and administrative | 9.24M USD | 9.23M USD | 6.52M USD | 3.32M USD | 1.06M USD |
| Operating expenses | 15.82M USD | 13.74M USD | 8.89M USD | 4.47M USD | 1.58M USD |
| Interest income | 247K USD | 251K USD | — | — | — |
| Interest expense | 204K USD | 20K USD | 147K USD | 654K USD | 4K USD |
| Depreciation and amortization | 832K USD | 573K USD | 437K USD | 94K USD | — |
| Operating income | −16.65M USD | −13.74M USD | −8.89M USD | −4.47M USD | −1.58M USD |
| Net income | −18.65M USD | −11.16M USD | −16.49M USD | −5.12M USD | −1.58M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 44%
- 4 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -327.06%
- 9 comparable reports
- Latest EPS result
- -0.66
- Estimate -0.93 · Beat by 29.03%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$180
12400.00% upsideRating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
FBLG news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 30, 2026 | 1:20 | — | — |
Effective Mar 30, 2026
1:20
FBLG peers
ETFs holding FBLG
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research FBLGresearch.disclaimer